Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer
Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel
Neurotech Chief Medical Officer authors article in Ophthalmology Times
A roadmap to preserving the prime years of patients diagnosed with MacTel, was published by Ophthalmology Times and written by Thomas Aaberg, Jr., explores the progression of MacTel and the… read more
Neurotech Chief Medical Officer authors article in The Ophthalmologist
The article, A Tiny Factory: Scaffolding a solution to macular telangiectasia with encapsulated cell therapy, was published by The Ophthalmologist and written by Thomas Aaberg, Jr., explores how ECT can… read more
Neurotech Pharmaceuticals Appoints Thomas Aaberg Jr., M.D. as Chief Medical Officer
Fast Track Designation Granted for Macular Telangiectasia Type 2 (MacTel)
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.
Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.
Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implant
Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases by Kauper et al.